Results 211 to 220 of about 8,055 (251)

Effects of Tirzepatide in Obesity-Related HFpEF by Sex: A Prespecified Secondary Analysis From the SUMMIT Trial. [PDF]

JACC Heart Fail
Borlaug BA, Zile MR, Kramer CM, Litwin SE, Ye W, Ou Y, Hurt K, Murakami M, Packer M, SUMMIT Trial Group.   +9 more
europepmc   +1 more source

SURPASS‐CVOT and the Emerging Biology of Cardiometabolic Benefit

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 8753-8756, October 2026.
Salvatore Corrao, Francesco Cosentino, Massimo Federici   +2 more
wiley   +1 more source

Associations Between GLP‐1 Receptor Agonists and Alopecia: A Multi‐Centre Retrospective Analysis and Public Interest Trends

JEADV Clinical Practice, Volume 5, Issue 3, Page 901-905, September 2026.
ABSTRACT Background There is a growing body of literature suggesting that GLP‐1 receptor agonists (GLP‐1RAs) may be associated with hair loss; however, primary literature is sparse. Additionally, it is not well‐established which types of hair loss may be associated with GLP‐1RA use. Objectives This study aims to assess associations between GLP‐1RAs and
Lauren M. Ching, Christopher A. Guirguis, Joe K. Tung   +2 more
wiley   +1 more source

Comparative effectiveness of tirzepatide and DPP-4 inhibitors in type 2 diabetes with heart failure. [PDF]

Diab Vasc Dis Res
Mortada I, Paul K, Chammany M, Abraham Y, Devulapally K, Lee AW, Mansour S, Chatila K, Boyars MC, Jehle D, Blackwell TA, Jneid H.   +11 more
europepmc   +1 more source

Metabolic Syndrome: From Mechanisms to Therapeutic Interventions

MedComm, Volume 7, Issue 9, September 2026.
A comprehensive overview of molecular mechanisms delves into the potential disease mechanisms of metabolic syndrome, including complex mechanisms such as insulin resistance, chronic low‐grade inflammation, oxidative stress, and epigenetic modifications, and how these mechanisms contribute to the development of metabolic syndrome. Here, the relationship
Mengyao Yan, Qian Xiang
wiley   +1 more source

Clinical Implications of Mounjaro (Tirzepatide) for Breast Cancer Detection and Management: A Narrative Review. [PDF]

Cureus
Mady R, Tafazal H, Soliman H, Ramadan A, Hajaj M.   +4 more
europepmc   +1 more source

Evaluating the Evolving Real‐World Adverse Events of GLP‐1RAs Using FDA Adverse Event Reporting System (FAERS)

Obesity, Volume 34, Issue S2, Page 101-108, September 2026.
Web portal for interrogating Adverse Events of GLP‐1 RA in diabetes vs weight control/obesity. ABSTRACT Objective This study aimed to assess the spectrum and frequency of adverse events (AEs) linked to glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) using the US FDA Adverse Event Reporting System (FAERS).
David Stone, Mary Playdon, Stephen D. Hursting, Aik Choon Tan   +3 more
wiley   +1 more source

Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide: A Target Trial Emulation. [PDF]

JACC Adv
Azzam AY, Essibayi MA, Rai P, Salim HA, Alhasan MS, Anindo M, Hashem A, Dmytriw AA, Altschul DJ, Yedavalli VS, Feltrin F, Singh S, Milburn J, Lakhani DA.   +13 more
europepmc   +1 more source

Responses to GLP‐1RA in White and Black Adults With Obesity: Insights From Generalized Additive Mixed Models of EHR Data

Obesity, Volume 34, Issue S2, Page 109-118, September 2026.
ABSTRACT Objective This study examined racial differences in weight loss and clinical response to glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) therapy among adults with obesity using real‐world data. Methods We retrospectively analyzed our institution's Research Data Warehouse (RDW) containing deidentified data from electronic health records ...
Jordan H. Mallette, Joshua S. Speed, Seth T. Lirette, Daniel Moore, John S. Clemmer   +4 more
wiley   +1 more source